pharmaphorum

SEPTEMBER 10, 2020

The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies. subtilis spores engineered to present SARS-CoV-2 antigens to the mucosal immune system.

Vaccination 133

Vaccination Vaccine Bacterium Antibody 133

Scienmag

MARCH 22, 2021

Credit: UNM School of Engineering A University of New Mexico research team conducted a data analysis that has found that as a larger portion of the population gets vaccinated against COVID-19, it becomes economically advantageous to start relaxing social distancing measures and open businesses.

Vaccination 94

Vaccination Vaccine Engineer Research 94

Scienmag

OCTOBER 12, 2020

Credit: WEI Wei Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use.

Vaccination 93

Vaccination Vaccine Development Scientist 93

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 22, 2022

The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB). The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells.

Vaccination 100

Vaccination Vaccine Research Bacteria 100

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

BioSpace

AUGUST 6, 2020

CoV2373, a recombinant vaccine engineered from the genetic sequence of SARS-CoV-2, in India and in low- and middle-income countries. Novavax said the agreement will allow for the development and distribution of NVX?CoV2373,

Vaccination 91

Vaccination Vaccine Development Engineer 91

XTalks

NOVEMBER 23, 2020

Adding to recent announcements from Pfizer and Moderna on the efficacy of their COVID-19 vaccine candidates, AstraZeneca and Oxford revealed today that their vaccine contender is 70 percent effective, and could be as high as 90 percent. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

pharmaphorum

AUGUST 23, 2021

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

Scienmag

MARCH 10, 2022

Close interactions with infectious disease set both University of California, Santa Cruz graduate student Ana Nuñez Castrejon and Associate Professor of Biomolecular Engineering Rebecca DuBois on the path of studying Respiratory syncytial virus (RSV), a common and sometimes dangerous respiratory disease for which there is not currently a vaccine.

Immune Response 77

Immune Response Vaccination Vaccine Protein 77

BioPharma Reporter

AUGUST 2, 2022

GreenLight Biosciences and Samsung Biologics have completed the first commercial-scale engineering run under the companiesâ mRNA production partnership: ahead of a COVID-19 vaccine booster clinical trial due to start later this year.

Engineer 52

Engineer Vaccination Vaccine Clinical Trials 52

Scienmag

JANUARY 6, 2021

Funding for device that gives vaccine and monitors response Credit: IMPACT, Swansea University Researchers at Swansea University have received £230,000 to develop the world’s first smart vaccine device that will both deliver the COVID-19 vaccine and measure its efficacy through monitoring the body’s associated response.

Vaccination 94

Vaccination Vaccine Research Development 94

Scienmag

JANUARY 4, 2021

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.

Vaccination 98

Vaccination Vaccine Antibody Development 98

BioPharma Reporter

SEPTEMBER 14, 2023

Vaxess Technologies, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, has announced an additional $9 million in venture capital funding, with investors including RA Capital, The Engine, and GHIC, and Ulu Ventures.

Vaccination 64

Vaccination Vaccine Life Science Engineer 64

BioTech 365

SEPTEMBER 7, 2021

CSE: DTC FSE: DTC OTC: DTCFF PRESS RELEASE DEFENCE THERAPEUTICS DEVELOPMENT PROGRAM TO ENGINEER A NEW HPV VACCINE … Continue reading → . / Key word(s): Miscellaneous 07.09.2021 / 08:30 The issuer is solely responsible for the content of this announcement.

Engineer 40

Engineer Vaccination Vaccine Development 40

Scienmag

JULY 8, 2021

A new vaccine technology combining capture of bacterial pathogens with effective immune-reprogramming biomaterials could be applied to a broad spectrum of infectious diseases Credit: Wyss Institute at Harvard University.

Vaccination 98

Vaccination Vaccine Bacteria Drugs 98

pharmaphorum

MARCH 2, 2021

The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. A combination of urgent need, unprecedented investments, and advances in genetic engineering has allowed what was once mere speculation to become not only our reality, but our future.

Genetics 52

Genetics Vaccination Vaccine Development 52

Scienmag

APRIL 22, 2021

In February, the researchers introduced […].

Production 84

Production Vaccination Vaccine Protein 84

Scienmag

JANUARY 8, 2021

Across the world, health care workers and high-risk groups are beginning to receive COVID-19 vaccines, offering hope for a return to normalcy amidst the pandemic. However, the vaccines authorized for emergency use in the U.S. require two doses to be effective, which can create problems with logistics and compliance.

Vaccination 75

Vaccination Vaccine Antibody Compliance 75

pharmaphorum

MARCH 30, 2022

CureVac and GlaxoSmithKline’s first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical trial last year, but they aren’t giving up. ” The post CureVac and GSK try again with COVID-19 vaccine appeared first on.

Vaccination 64

Vaccination Vaccine Protein Antibody 64

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. Since 2004, the NIAID has been championing the discovery and development of the cytomegalovirus (CMV) vector used to deliver the HIV vaccine material to the immune system without causing disease.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

pharmaphorum

JULY 6, 2022

BioNTech has responded to a patent infringement lawsuit filed by fellow German biotech CureVac over its COVID-19 vaccine, saying it will “vigorously” defend itself. ” CureVac’s first attempt to develop a COVID-19 vaccine ended in failure, and it is now working on a second version with partner GSK.

Vaccination 98

Vaccination Vaccine Sales Engineer 98

XTalks

FEBRUARY 11, 2021

Amidst growing global shortages of COVID-19 vaccine supplies, inaugural (by way of authorizations/approvals) COVID-19 vaccine maker Pfizer is addressing the issue by working to cut the manufacturing time of its vaccine by almost half. Related: Pharma Rivals Step Up to Assist with COVID-19 Vaccine Production.

Manufacturing 52

Manufacturing Vaccination Vaccine DNA 52

Roots Analysis

MARCH 16, 2023

The IVT mRNAs are structurally similar to natural mRNAs, these synthetic mRNAs can be used to express proteins through genetic engineering. It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Scienmag

MARCH 19, 2021

Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds. MIT researchers have now developed a vaccination strategy that can create an army of T cells that are […].

Vaccination 48

Vaccination Vaccine Immune Response Development 48

The Pharma Data

SEPTEMBER 30, 2021

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccination 52

Vaccination Vaccine Immune Response Licensing 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

Pfizer

APRIL 26, 2023

But the underlying question is always the same: How will Pfizer and BioNTech ensure a seamless distribution of our vaccine? With the pandemic still raging, our vaccine will be in high demand and, upon authorization or approval, rapidly utilized to help beat back the virus. In the U.S.,

Vaccination 52

Vaccination Vaccine Manufacturing Containment 52

The Pharma Data

NOVEMBER 9, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. GAITHERSBURG, Md., Glenn, M.D., and globally.”. government.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Scienmag

APRIL 12, 2021

Credit: UPMC PITTSBURGH, April 13, 2021 – What can vaccine proponents, clinicians and public health communicators learn from “anti-vaxxers?” ” A lot, according to new guidance for pro-vaccination social media events written by University of Pittsburgh health scientists.

Vaccination 53

Vaccination Vaccine Research Scientist 53

Scienmag

MAY 24, 2021

The vaccine, made of disease-fighting proteins, could boost efficacy, accelerate production of seasonal flu vaccines Credit: University at Buffalo. — An experimental flu vaccine consisting of billions of tiny spherical sacs that carry infection-fighting proteins throughout the body has proven effective in preclinical studies.

Vaccination 52

Vaccination Vaccine Protein Trials 52

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Vaccines Taskforce and National Institute for Health Research played pivotal roles in the rapid recruitment and enrollment of volunteers. and Australia.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

Scienmag

MAY 12, 2021

Misleading claims about COVID-19 vaccines can negatively impact public confidence in immunisation uptake, a new UNSW Sydney study reveals. Misleading claims about COVID-19 vaccines can negatively impact public confidence in immunisation uptake, a new UNSW Sydney study reveals.

Vaccination 51

Vaccination Vaccine Engineer Medicine 51

The Pharma Data

OCTOBER 27, 2020

WASHINGTON–( BUSINESS WIRE )– When COVID-19 vaccines become available in the United States, there won’t be enough to vaccinate everyone right away, and states will need to allocate them to their highest priority populations. Visit the COVID-19 Vaccine Allocation Planner at [link] (Graphic: Business Wire).

Vaccination 52

Vaccination Vaccine Engineer Development 52

The Pharma Data

MAY 4, 2021

. Pfizer plans to file for full FDA approval of Covid vaccine at the end of this month ( CNBC ). The FDA is set to authorize the Pfizer-BioNTech vaccine for those 12-15 years old by early next week. Pfizer Reaps Hundreds of Millions in Profits From Covid Vaccine ( NYTimes ) ( WSJ ) ( Endpoints ) ( Reuters ).

Vaccination 52

Vaccination Vaccine FDA Approval Regulation 52

The Pharma Data

DECEMBER 10, 2020

–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–(

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

DECEMBER 16, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. About NVX-CoV2373.

Protein 52

Protein Vaccination Vaccine Immune Response 52